Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

Preclinical efficacy of the synergistic Ruxolitinib–Homoharringtonine combination in TP53-mutated myeloproliferative neoplasms progressing to sAML

View Full Paper
Ask AI
Bookmark
Share

Authors

RLRumeng LiJHJiansong Huang

Discussion

Loading...

Member takes

Overview

Preclinical findings reveal that Ruxolitinib and Homoharringtonine combination improves apoptosis and limits tumor growth in TP53-mutated myeloproliferative neoplasms.

Key Points

  • Combination treatment significantly enhanced apoptosis in myeloproliferative neoplasms via pronounced cell viability suppression and tumor burden reduction.
  • In SET-2 and HEL cell lines, the Ruxolitinib and Homoharringtonine combination showed significant synergy confirmed by combination indices < 1.
  • RNA-seq and Western blotting analysis indicated substantial alterations in cell-cycle and apoptosis-related gene expressions, particularly in TP53 pathways.
  • The preclinical efficacy of this combination strategy highlights its potential for enhancing treatment in patients with TP53-mutated myeloproliferative neoplasms.

Cite This Study

Li et al. (2025) studied this question.

synapsesocial.com/papers/69362f5d4fa91c937236dbe5https://doi.org/10.1182/blood-2025-7270
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Decitabine enhances the cytotoxic effect of ruxolitinib in myeloproliferative neoplasms by targeting SR splicing factors2025
  2. 2Direct small molecule inhibition of RAS enhances JAK2 inhibitor therapy in preclinical models of myeloproliferative neoplasms2025
  3. 3Genome-wide CRISPR-Cas9 screen reveals novel ruxolitinib-resistance targets in myeloproliferative neoplasms2025
  4. 4Ruxolitinib combined with P-gemox in adult patients with newly diagnosed aggressive natural killer cell leukemia2025
  5. 5Enhanced antileukemic activity of momelotinib in combination with venetoclax and azacitidine compared to gilteritinib-based combination2025